---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-26-000002"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2026-02-02T23:59:59+00:00"
generated_at: "2026-05-16T05:37:01.648901+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# vTv expands HPP737 license to worldwide; Newsoara pays $20M upfront, up to $115M milestones plus royalties

## Summary
- Second Amendment grants Newsoara global rights to PDE4 inhibitor HPP737 upon $20M upfront payment.
- Up to $50M in development milestones and $65M in sales-based milestones; royalties mid-single digits.
- Prior amendment became null and void in June 2025; this replaces it.
- Agreement with Newsoara Biopharma Co., Ltd., a Chinese partner.

## SEC filing metadata
- accession: 0001641489-26-000002
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2026-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000002/0001641489-26-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000002/vtvt-20260130.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-26-000002
- JSON: https://secwatch.observer/filing/0001641489-26-000002.json
- Plain text: https://secwatch.observer/filing/0001641489-26-000002.txt

## Key facts
- Material Agreements
  vTv Therapeutics Inc. entered into Second Amendment to License Agreement with Newsoara Biopharma Co., Ltd. valued at $20 million upfront fee, up to $50 million in development milestones, $65 million in sales-related m (effective 2026-01-30).
  - Action: entry
  - Agreement: license
  - Counterparty: Newsoara Biopharma Co., Ltd.
  - Value: $20 million upfront fee, up to $50 million in development milestones, $65 million in sales-related m
  - Effective: 2026-01-30
  source text: On January 30, 2026, vTv Therapeutics LLC (“vTv LLC” or the "Company"), a subsidiary of vTv Therapeutics Inc., entered into the Second Amendment to License Agreement with Newsoara Biopharma Co., Ltd. (“Newsoara”) (the “Second Amendment”) to amend the License Agreement previously entered into between vTv LLC and Newsoara on May 31, 2018 (the “Original Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000002/0001641489-26-000002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.